HIF ‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

Abstract A classic response to systemic hypoxia is the increase in red blood cell production. This response is controlled by the prolyl hydroxylase domain/hypoxia‐inducible factor (HIF) pathway, which regulates a broad spectrum of cellular functions. The discovery of this pathway as a key regulator of erythropoiesis has led to the development of small molecules that stimulate the production of endogenous erythropoietin and enhance iron metabolism. This review provides a concise overview of the cellular and molecular mechanisms that govern HIF‐induced erythropoietic responses and provides an update on clinical experience with compounds that target HIF‐prolyl hydroxylases for anemia therapy.
Source: Hemodialysis International - Category: Hematology Authors: Tags: SCHOLARLY REVIEW Source Type: research